Immunotherapy targeting HER2 with genetically modified T cells eliminates tumor-initiating cells in osteosarcoma

Cancer Gene Therapy

Volumn 19, Issue 3, 2012, Pages 212-217

  Rainusso, N ^a   Brawley, V S ^a   Ghazi, A ^a   Hicks, M J ^b   Gottschalk, S ^a   Rosen, J M ^b   Ahmed, N ^a  

^a CENTER FOR CELL AND GENE THERAPY   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

chimeric antigen receptor; HER2; immunotherapy; osteosarcoma; tumor initiating cells

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; LYMPHOCYTE ANTIGEN RECEPTOR; METHOTREXATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENICITY; CELL ISOLATION; CONTROLLED STUDY; DNA MODIFICATION; DRUG CYTOTOXICITY; EXPLANT; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNOTHERAPY; MALE; MOUSE; NONHUMAN; ORTHOTOPIC TRANSPLANTATION; OSTEOSARCOMA; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR CELL; TUMOR INITIATING CELL;

MUS;

EID: 84857115215     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/cgt.2011.83     Document Type: Article

References (23)

1. Marina N, Gebhardt M, Teot L, Gorlick R. Biology and therapeutic advances for pediatric osteosarcoma. Oncologist 2004; 9: 422-441. (Pubitemid 39014554)
2. Siclari VA, Qin L. Targeting the osteosarcoma cancer stem cell. J Orthop Surg Res 2010; 5: 78.
3. Rosen JM, Jordan CT. The increasing complexity of the cancer stem cell paradigm. Science 2009; 324: 1670-1673.
4. Adhikari AS, Agarwal N, Wood BM, Porretta C, Ruiz B, Pochampally RR et al. CD117 and Stro-1 identify osteosarcoma tumor-initiating cells associated with metastasis and drug resistance. Cancer Res 2010; 70: 4602-4612.
5. Tirino V, Desiderio V, d0Aquino R, De Francesco F, Pirozzi G, Graziano A et al. Detection and characterization of CD133+ cancer stem cells in human solid tumours. PLoS One 2008; 3: e3469.
6. Murase M, Kano M, Tsukahara T, Takahashi A, Torigoe T, Kawaguchi S et al. Side population cells have the characteristics of cancer stem-like cells/cancer-initiating cells in bone sarcomas. Br J Cancer 2009; 101: 1425-1432.
7. Gibbs CP, Kukekov VG, Reith JD, Tchigrinova O, Suslov ON, Scott EW et al. Stem-like cells in bone sarcomas: implications for tumorigenesis. Neoplasia 2005; 7: 967-976.
8. Fujii H, Honoki K, Tsujiuchi T, Kido A, Yoshitani K, Takakura Y. Sphere-forming stem-like cell populations with drug resistance in human sarcoma cell lines. Int J Oncol 2009; 34: 1381-1386.
9. Lou N, Wang Y, Sun D, Zhao J, Gao Z. Isolation of stemlike cells from human MG-63 osteosarcoma cells using limiting dilution in combination with vincristine selection. Indian J Biochem Biophys 2010; 47: 340-347.
10. Gorlick R, Huvos AG, Heller G, Aledo A, Beardsley GP, Healey JH et al. Expression of HER2/erbB-2 correlates with survival in osteosarcoma. J Clin Oncol 1999; 17: 2781-2788. (Pubitemid 29415235)
11. Morris CD, Gorlick R, Huvos G, Heller G, Meyers PA, Healey JH. Human epidermal growth factor receptor 2 as a prognostic indicator in osteogenic sarcoma. Clin Orthop Relat Res 2001; 382: 59-65. (Pubitemid 32047430)
12. Ahmed N, Salsman VS, Yvon E, Louis CU, Perlaky L, Wels WS et al. Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression. Mol Ther 2009; 17: 1779-1787.
13. Rainusso N, Man TK, Lau CC, Hicks J, Shen JJ, Yu A et al. Identification and gene expression profiling of tumorinitiating cells isolated from human osteosarcoma cell lines in an orthotopic mouse model. Cancer Biol Ther 2011; 12: 278-287.
14. Zhang M, Behbod F, Atkinson RL, Landis MD, Kittrell F, Edwards D et al. Identification of tumor-initiating cells in a p53-null mouse model of breast cancer. Cancer Res 2008; 68: 4674-4682.
15. Gottschalk S, Edwards OL, Sili U, Huls MH, Goltsova T, Davis AR et al. Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies. Blood 2003; 101: 1905-1912. (Pubitemid 36237592)
16. Vera J, Savoldo B, Vigouroux S, Biagi E, Pule M, Rossig C et al. Tlymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells. Blood 2006; 108: 3890-3897. (Pubitemid 44864573)
17. Jaffe N, Gorlick R. High-dose methotrexate in osteosarcoma: let the questions surcease-time for final acceptance. J Clin Oncol 2008; 26: 4365-4366.
18. Wen YH, Koeppen H, Garcia R, Chiriboga L, Tarlow BD, Peters BA et al. Epidermal growth factor receptor in osteosarcoma: expression and mutational analysis. Hum Pathol 2007; 38: 1184-1191. (Pubitemid 47058157)
19. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 2008; 8: 755-768.
20. Atkinson RL, Zhang M, Diagaradjane P, Peddibhotla S, Contreras A, Hilsenbeck SG et al. Thermal enhancement with optically activated gold nanoshells sensitizes breast cancer stem cells to radiation therapy. Sci Transl Med 2010; 2: 55ra79.
21. Li X, Lewis MT, Huang J, Gutierrez C, Osborne CK, Wu MF et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J Natl Cancer Inst 2008; 100: 672-679.
22. Boman BM, Wicha MS. Cancer stem cells: a step toward the cure. J Clin Oncol 2008; 26: 2795-2799.
23. West GW, Weichselbaum R, Little JB. Limited penetration of methotrexate into human osteosarcoma spheroids as a proposed model for solid tumor resistance to adjuvant chemotherapy. Cancer Res 1980; 40: 3665-3668. (Pubitemid 10003768)